Albert Bourla (Evan Vucci, AP Images)
November 2, 2021 09:50 AM EDT
Coronavirus

Covid-19 roundup: Pfiz­er rais­es 2021 vac­cine sales fore­cast to $36B; Lil­ly lands $1.3B treat­ment deal with US gov­ern­ment

Zachary Brennan

Senior Editor

Pfiz­er’s Covid-19 vac­cine in 2021 is quick­ly be­com­ing the best-sell­ing med­ical prod­uct of all time in terms of an­nu­al sales.

The com­pa­ny on Tues­day re­port­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times